

# Bert Rein Named a Leading Food & Drug Attorney

September 19, 2005

Washington, DC—Wiley Rein & Fielding named partner Bert W. Rein has been selected a “Leading Food & Drug Lawyer” by *Legal Times* in an article listing the top 11 DC-area attorneys in this legal arena. Rein is recognized as “a key player in some of the highest-profile food-and-drug conflicts in recent years.”

The *Legal Times* profile details some of Rein’s many successes in the field and notes his “record of successfully fighting off attempts by the government to expand oversight of industry.” Indeed, Rein told the paper, “If my practice has a theme, it’s the limits of government authority and the proper boundaries of power.”

Rein occupies a distinct place in the food and drug bar, where he is known for his extensive knowledge of administrative law and superior litigation skills. The span of his practice is diverse, encompassing matters ranging from First Amendment rights of industries regulated by the U.S. Food and Drug Administration to product liability issues and reform. Jeffrey Chasnow, senior corporate counsel at Pfizer Inc. told the paper, “Bert has a unique mastery of FDA issues” as well as “very astute and very strategic judgment” and the ability to “come up with workable solutions that make sense.”

Also commenting on his ability to develop novel and creative solutions to complex and difficult legal and business problems, Marjorie Powell, senior assistant general counsel for the Pharmaceutical Research and Manufacturers of America told *Legal Times* that Rein, “has a breadth of experience and the ability to remember cases and legal theories and make connections that are not immediately apparent. He can come up with a whole variety of potential options and has the ability to evaluate their likelihood of

## Related Professionals

Bert W. Rein  
Founder  
202.719.7080  
[brein@wiley.law](mailto:brein@wiley.law)

## Practice Areas

Antitrust  
Class Action  
Food & Drug  
Intellectual Property  
Issues and Appeals  
Litigation  
Public Policy

success.”

Rein, a prolific author and speaker, recently served as a member of the Editorial Board of the *Pharmaceutical & Medical Device Law Bulletin*. Currently a director of the National Chamber and Litigation Counter, he was a three-term director of U.S. Chamber of Commerce and is a past president of the International Trade Commission Trial Lawyers Association. Rein received his LL.B., *summa cum laude*, from Harvard Law School.

[Read article.](#)